Tempest Therapeutics Inc (TPST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of -9.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($822.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tempest Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Tempest Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TPST capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NSN Co. Ltd
KQ:031860
|
-0.143x |
|
TalkPool AG
ST:TALK
|
0.305x |
|
Japan Vietnam Medical Instrument JSC
VN:JVC
|
0.005x |
|
Draper Esprit PLC
LSE:GROW
|
0.024x |
|
Kainos Group PLC
LSE:KNOS
|
0.379x |
|
Kier Group PLC
LSE:KIE
|
0.457x |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
0.058x |
|
Nukkleus Inc
NASDAQ:NUKK
|
0.033x |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Tempest Therapeutics Inc (TPST) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.67 Million | $-26.82 Million | -4.022x | -132.93% |
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more